1. Ansari, B., Coates, P. J., Greenstein, B. D. & Hall, P. A. (1993). In situ end-labeling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 170: 1–8.
2. Blagosklonny, M. V., Prabhu, N. S. & El-Deiry, W. S. (1997). Defects in p21/WAF1/CIP1, Rb, and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res 57: 320–325.
3. Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F. & Allred, D. C. (1993). p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53: 3369–3373.
4. Breslow, N. E. & Day, N. E. (1980). The Analysis of Case Control Studies. IARC Scientific Publications, no. 32. IARC: Lyon
5. Bubendorf, L., Sauter, G., Moch, H., Jordan, P., Blochlinger, A., Gasser, T. C. & Mihatsch, M. J. (1996). Prognostic significance of Bcl-2 in clinically localized prostate cancer. Am J Pathol 148: 1557–1565.